For children with unexplained fevers, painful mouth sores, and gut inflammation that resemble Behçet's disease (BD) but do not fully meet diagnostic criteria, clinicians have long faced a diagnostic challenge. Now, researchers at Peking Union Medical College Hospital in Beijing have published a comprehensive review in the World Journal of Pediatrics that formalizes the concept of Behçet's spectrum disorders (BSD), a framework that may help solve this puzzle.
Behçet's disease is a systemic vasculitis characterized by recurrent oral and genital ulcers, but pediatric presentations are often partial or atypical, complicating diagnosis. Moreover, a growing number of monogenic autoinflammatory disorders produce nearly identical mucocutaneous and gastrointestinal symptoms yet require different treatments. This diagnostic overlap frequently leads to misdiagnosis, inappropriate therapy, and prolonged suffering. Although the BSD concept was introduced in 2020, a practical framework for early recognition and genetic prioritization in children has remained elusive.
The review proposes a two-tier classification grounded in genetic and mechanistic evidence. The core BSD tier comprises monogenic diseases that directly disrupt NF-κB or JAK-STAT signaling, including HA20 (caused by TNFAIP3 mutations), RELA haploinsufficiency, NFKB1 haploinsufficiency, and ELF4 deficiency. These conditions consistently feature recurrent mucocutaneous ulceration. The peripheral BSD tier includes polygenic or multifactorial entities such as recurrent aphthous stomatitis (RAS), PFAPA syndrome, DADA2, and trisomy 8-associated disease, which exhibit partial clinical overlap. The authors identify NF-κB and JAK-STAT as central inflammatory hubs common across the spectrum, providing a rational basis for grouping these disorders. They also delineate exclusion criteria to distinguish true spectrum members from phenotypic mimics like LIG4 deficiency and IKBKG (NEMO) mutations.
Clinically, the BSD framework enables earlier recognition of Behçet-like phenotypes and guides rational genetic testing, allowing targeted therapies such as IL-1, TNF, or JAK inhibitors for specific subsets. It also helps exclude non-spectrum mimics, avoiding unnecessary investigations. The authors emphasize that the framework is especially valuable in early-onset or atypical cases, where genetic testing can distinguish between conditions that look alike but respond to different treatments. "We're not saying these are all the same disease—they're not," the authors stated. "But they converge on the same inflammatory circuits. If a child shows up with recurrent mouth ulcers, fever, and gut inflammation that doesn't quite fit Behçet's criteria, the BSD framework gives us a roadmap for what to test for and why."
This mechanism-oriented approach marks a paradigm shift from purely symptom-based classification to stratified, biology-driven nosology. By unifying disparate inflammatory disorders under shared pathogenic axes, it fosters collaborative research and paves the way for biomarker discovery and mechanism-based trials. Ultimately, the framework empowers pediatricians to move towards precision medicine, offering hope for children with complex, refractory inflammatory conditions that have long defied conventional diagnosis and treatment.
